From what I've seen so far from this company you could just do...

From what I've seen so far from this company you could just do both, take a few gs and play long and a few gs to play short term, or you could do it by shares, I think hiv is a good bet as far as hep b goes it may only take us to 10 a share Aus, but the winner in that space will be ARWR first us second so we should be fine, there will be a short term run up to 1-2 pershare because the hep c data I think will show viral load reduction of course their will then be a cr .if cr is a purchase in full it will the stock price will continue to bubble if its dilution it will of course sink. On the question of touting the science, the technology will be commercialized, but I think hiv is more than likely the golden goose